J
Jing Chen
Researcher at Pfizer
Publications - 3
Citations - 172
Jing Chen is an academic researcher from Pfizer. The author has contributed to research in topics: Glucokinase & Glucose homeostasis. The author has an hindex of 3, co-authored 3 publications receiving 160 citations.
Papers
More filters
Journal ArticleDOI
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Jeffrey A. Pfefferkorn,Angel Guzman-Perez,John Litchfield,Robert J. Aiello,Judith L. Treadway,John C. Pettersen,Martha L. Minich,Kevin J. Filipski,Christopher S. Jones,Meihua Tu,Gary Erik Aspnes,Hud Lawrence Risley,Jianwei Bian,Benjamin D. Stevens,Patricia Bourassa,Theresa D’Aquila,Levenia Baker,Nicole Barucci,Alan Robertson,Francis Bourbonais,David R. Derksen,Margit MacDougall,Over Cabrera,Jing Chen,Amanda L. Lapworth,James A. Landro,William J. Zavadoski,Karen Atkinson,Nahor Haddish-Berhane,Beijing Tan,Lili Yao,Rachel E. Kosa,Manthena V.S. Varma,Bo Feng,David B. Duignan,Ayman El-Kattan,Sharad B. Murdande,Shenping Liu,Mark Ammirati,John D. Knafels,Paul DaSilva-Jardine,Laurel Sweet,Spiros Liras,Timothy P. Rolph +43 more
TL;DR: 19 is identified as a potent glucokinase activator with a greater than 50-fold liver-to-pancreas ratio of tissue distribution in rodent and non-rodent species, leading to its selection as a clinical development candidate for treating type 2 diabetes.
Journal ArticleDOI
Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus
Jeffrey A. Pfefferkorn,Angel Guzman-Perez,Peter J. Oates,John Litchfield,Gary Erik Aspnes,Arindrajit Basak,John William Benbow,Martin A. Berliner,Jianwei Bian,Chulho Choi,Kevin Daniel Freeman-Cook,Jeffrey W. Corbett,Mary Theresa Didiuk,Joshua R. Dunetz,Kevin J. Filipski,William M. Hungerford,Christopher S. Jones,Karki Kapil Kumar,Anthony Lai Ling,Jian-Cheng Li,Leena Patel,Christian Perreault,Hud Lawrence Risley,James Saenz,Wei Song,Meihua Tu,Robert J. Aiello,Karen Atkinson,Nicole Barucci,David A. Beebe,Patricia Bourassa,Francis Bourbounais,Anne M. Brodeur,Rena Burbey,Jing Chen,Theresa D’Aquila,David R. Derksen,Nahor Haddish-Berhane,Cong Huang,James A. Landro,Amanda L. Lapworth,Margit MacDougall,David E. Perregaux,John C. Pettersen,Alan Robertson,Beijing Tan,Judith L. Treadway,Shenping Liu,Xiayang Qiu,John D. Knafels,Mark Ammirati,Xi Song,Paul DaSilva-Jardine,Spiros Liras,Laurel Sweet,Timothy P. Rolph +55 more
TL;DR: This work has investigated a series of substituted 2-methylbenzofurans as “partial activators” of the glucokinase enzyme leading to the identification of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benz ofuran-4-yloxy)pyrimidine- 2-carboxamide as an early development candidate.
Journal ArticleDOI
Modulation of glucokinase by glucose, small-molecule activator and glucokinase regulatory protein: steady-state kinetic and cell-based analysis.
TL;DR: This work characterizes the modulation of GK by a novel GKA that may enable the design of new and improved GKAs, and shows that GKRP (GK regulatory protein) is a slow tight-binding inhibitor of Gk.